Posts tagged PDL1
Management of Advanced Disease in NSCLC
Management of Advanced Disease in NSCLC

Lung cancer remains the leading cause of cancer death world-wide. This is in part due patients presenting late with disseminated disease and despite recent advances, a limited therapeutic landscape... Despite these advances there remains a significant unmet clinical need with much research needed to elucidate the optimal treatment paradigm to improve response rates, mortality and quality of life for patients with advanced NSCLC. READ ARTICLE

Encyclopedia of Respiratory Medicine (Second Edition) DOI:10.1016/B978-0-08-102723-3.00265-1

Authors: Alice Davies, Martin Forster

Read More
EditorialKirk SmithAdenocarcinoma, Advanced lung cancer, Atezolizumab, Carboplatin, Chemotherapy, Cisplatin, Doxcetaxal, Driver mutations, Gemcitabine, Immunotherapy, Lung cancer, Metastatic lung cancer, Nivolumab, Non small cell, Palliative care, PD1, PDL1, Pembrolizumab, Small cell, Smoking, Smoking cessation, Squamous cell carcinoma, Targeted therapies, Treatment, Vinorelbine